Does HIMS pay a dividend and is it safe?

Hims & Hers Health Inc. (HIMS) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / HIMS / dividends

CHE (83) LFST (67) OPCH (74) BTSG (67) ⌘ Pro Terminal →

Hims & Hers Health Inc. (HIMS) Dividend Safety Gauge & 10-Year DRIP Compounder

$25.24 -8.81% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $24.79

Hims & Hers Health Inc. (HIMS) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $6.46B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on HIMS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is HIMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Hims & Hers Health Inc. (NYSE: HIMS) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $25.24 (-8.81% 1D, market cap $6.46B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 11/20. Across 1015 tracked Health Care issuers, HIMS ranks #161 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does HIMS compare to CHE and LFST in the Health Care sector?

▼

Within the Health Care sector (Medical/Nursing Services), HIMS carries a Roarable C- (60/100 RQD), trailing P/E of 53.9x, gross margin of 73.8%, and ROIC of 8.4%. By comparison, CHE (Chemed Corp) holds a A- grade (83/100 RQD, P/E N/A, ROIC 23.4%, cap $6.96B) and LFST (LifeStance Health Group Inc.) posts a C+ grade (67/100 RQD, P/E N/A, ROIC 1.2%, cap $5.12B). Among the 5-stock peer group, OPCH leads on earnings multiple (23.0x) while CHE leads on capital efficiency (23.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for HIMS?

▼

Per HIMS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001773751), Hims & Hers Health Inc. generated $2.35B in revenue (+59.0% YoY), $128.4M in net income, and $194.4M in free cash flow against $2.15B in total assets and $726.2M in total debt. Key quantitative strengths: Strong cash generator (73.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $24.79 (-1.78%)🧬 Cannibal Buyback (-0.96% YoY Shares)⚙️ Cash Engine: 15/20 (B) • 8.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY • 53.5% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HIMS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (60/100 Composite)

🔍 WHY HIMS SCORES 60/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+15/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 8.3% FCF Margin ($194.4M FCF) & 73.8% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (23% of score)

Altman Z-Score 3.95 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Macro Regime Fit10/20 pts (-10 pt drag)

Macro rate sensitivity & RSI-14 (45.3) create a -10 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$27.72+5.4% Next Q

Q2 (-2Q)

Grade C+$29.21+0.4% Next Q

Q3 (-1Q)

Grade C+$29.32-13.9% Next Q

Current

Grade C-$25.24+0.4% Hist 90D α

Trajectory: B- (68) → C- (60)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the HIMS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 60/100 (C-) score, HIMS faces multiple-compression risk if 53.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Priced at 54x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($28.85) or 200D SMA ($27.00) invalidates the momentum regime and cuts Target Base ($25.47) toward Bear Floor ($19.87).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HIMS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HIMS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 60%NO 40%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.3% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $45,269

Est. Year-10 Shareholder Yield: $815/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.6K

Yr 1

$13.5K

Yr 2

$15.7K

Yr 3

$18.3K

Yr 4

$21.3K

Yr 5

$24.7K

Yr 6

$28.8K

Yr 7

$33.5K

Yr 8

$38.9K

Yr 9

$45.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in HIMS & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on HIMS and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HIMS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.44%▼ SUPPORT BREAKDOWN

2026-11-03O $29.67H $29.67L $25.24C $25.24VOL 10.86M

RES: $30.49SUP: $25.97SMA50: $28.85SMA200: $27.00

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HIMS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HIMS Butterfly Map → + Track HIMS →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

38.4%/yr Implied 5Y Growth

vs. +59.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on HIMS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HIMS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HIMS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HIMS)

Health Care Rank #161 of 1015 ⚔️ CHE vs HIMS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HIMS vs. CHE, LFST, OPCH, BTSG)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Hims & Hers Health Inc. (HIMS) ranks #161 by composite RQD confidence (60/100, grade C-) and #137 by equity capitalization ($6.46B). Within this direct 5-issuer industry benchmark cohort, OPCH leads on earnings valuation at 23.0x trailing P/E, while CHE leads on capital efficiency and profitability with 23.4% ROIC and 32.5% gross margin. CHE currently holds the highest overall quantitative score in the immediate peer group at 83/100 (A-) compared with HIMS at 60/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HIMS ACTIVE Hims & Hers Health Inc.	C-	60/100	53.9x	73.8%	8.4%	-8.81%	$6.46B	Benchmark Subject
CHE Chemed Corp	A-	83/100	—	32.5%	23.4%	+1.40%	$6.96B	/che-vs-hims →
LFST LifeStance Health Group Inc.	C+	67/100	—	—	1.2%	-1.04%	$5.12B	/lfst-vs-hims →
OPCH Option Care Health Inc.	B	74/100	23.0x	19.3%	11.9%	-0.44%	$4.77B	/opch-vs-hims →
BTSG BrightSpring Health Services Inc.	C+	67/100	63.0x	11.8%	5.5%	-0.94%	$13.24B	/btsg-vs-hims →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001773751 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hims & Hers Health Inc. (HIMS) reported GAAP revenue of $2.35B (+59.0% vs. FY2024 revenue of $1.48B , and +169.2% cumulative change since FY2023) , GAAP net income of $128.4M, operating cash flow of $300.0M, and free cash flow of $194.4M (+5.3% YoY). On the balance sheet, HIMS closed FY2025 with $2.15B in total assets against $726.2M in total debt (Altman Z-Score: 3.95, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.35B	$128.4M	$300.0M	$194.4M	$2.15B	$726.2M
FY2024 (FY)	2024-12-31	$1.48B	$126.0M	$251.1M	$184.6M	$707.5M	$103.9M
FY2023 (FY)	2023-12-31	$872.0M	-$23.5M	$73.5M	$34.2M	$3.81B	$890.9M

3. HIMS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HIMS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does HIMS compare to CHE and LFST in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for HIMS?

Where is HIMS trading relative to its 50-day, 200-day, and 52-week technical levels?

HIMS last traded at $25.24 (-8.81% on volume of 10,789,516 shares), positioning the stock -12.51% below its 50-day simple moving average ($28.85) and -6.52% below its 200-day simple moving average ($27.00). Across its 52-week range of $13.74 to $48.34, HIMS sits at the 33.2% percentile with a 14-day RSI of 45.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($22.09 to $28.39).

Direct Sub-Reports: HIMS RQD Cockpit HIMS 12M Forecast HIMS Earnings & Move HIMS Dividends & DRIP HIMS Insiders & 13F HIMS Whale Options HIMS Profit Sankey HIMS News & Why

ROARABLE RATING BRIEF • RQD 60/100 (C-) ✓ SEC XBRL & RQD VERIFIED

HIMS — Hims & Hers Health Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Hims & Hers Health Inc. (HIMS) earns a live Roarable RQD composite score of 60/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $25.24 (-8.81% 1D, market capitalization $6.46B).

Fundamental Cash Engine (15/20): Anchored by return on invested capital (ROIC) of 8.4%, gross margin of 73.8%, operating margin of 4.5%, and free cash flow yield of 2.81%.
Whale 13F & Options Flow (10/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (10/20) + Forensic Balance Sheet (14/20): Incorporates a 1.05x equity beta, Altman Z-Score of 3.95, Piotroski F-Score of 8/9, and Debt/Equity of 1.25x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Hims & Hers Health Inc. Is a NYSE-listed issuer classified under the Health Care sector and the Medical/Nursing Services industry,. Gross margin is 73.8% per the market data, indicating a high-margin revenue base relative to operating margin of 4.5%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Hims & Hers Health Inc. (HIMS) reported $2.35B in annual revenue (up from $1.48B in FY2024, +59.0% YoY) and $128.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($872.0M revenue, -$23.5M net income) through FY2025, HIMS scaled operating cash flow to $300.0M and free cash flow to $194.4M, backed by $2.15B in total assets against $726.2M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C- • RQD 60/100): Strong cash generator (73.8% gross margin)—profits are backed by real money, not accounting tricks. Free cash flow yield of 2.81% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 15/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $13.74 – $48.34 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 53.9x trailing P/E and 37.7x EV/EBITDA against 4.5% operating margins and a 1.05x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream dependencies, downstream customers, and sector correlations beyond the Health Care sector and Medical/Nursing Services industry classification are — Investors should note that second-order ripple analysis cannot be performed from this dataset.

Key Question #1: Can HIMS sustain or expand its 4.5% operating margin and 8.4% ROIC against Medical/Nursing Services peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $2.35B and free cash flow of $194.4M, how will capital allocation balance growth reinvestment against $726.2M in total debt?
Key Question #3: How sensitive is HIMS's 45.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.05x)?

HIMS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Hims & Hers Health Inc. (HIMS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to HIMS Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It

Yahoo Finance report covering Hims & Hers Health Inc. (HIMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Reuters • 1d ago

Hims & Hers Health launches online weight management service for men in Germany

Reuters report covering Hims & Hers Health Inc. (HIMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Hims & Hers Health climbs 10% amid recent volatile trading (HIMS:NYSE)

Seeking Alpha report covering Hims & Hers Health Inc. (HIMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Trefis • 1d ago

Should You Trim Or Add To Your Hims & Hers Position Now?

Trefis report covering Hims & Hers Health Inc. (HIMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Hims And Hers Health (HIMS) Stock May Trade At A Discount Despite Australia Launch

Yahoo Finance report covering Hims & Hers Health Inc. (HIMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 1d ago

Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights

Yahoo Finance report covering Hims & Hers Health Inc. (HIMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Hims & Hers Health, Inc. (HIMS) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Hims & Hers Health Inc. (HIMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today

Yahoo Finance report covering Hims & Hers Health Inc. (HIMS) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

HIMS Bull vs. Bear Conversation Board — What's Your Call at $25.24?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HIMS 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $33.49 (+21.0%)

📌 Pinned Debate

Revenue expanded from $872.0M in FY 2023 to $2.35B in FY 2025 while operating income turned positive to $105.6M, with a Piotroski F-S

Revenue expanded from $872.0M in FY 2023 to $2.35B in FY 2025 while operating income turned positive to $105.6M, with a Piotroski F-Score of 8 out of 9.. When you look under the hood at HIMS, Fundamental Cash Engine is 15/20 with 73.8% gross margins and 8.4% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (10/20) has been quietly accumulating below $48.34. My 12M target is $33.49.

SectorRotator 🐂 BULL

@ShortSeller_Dan Fair point on 53.9x trailing P/E, but you're ignoring the forward operating leverage in Medical/Nursing Services. If gross margin (73.8%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $22.70 (-18.0%)

Spot @ $27.68

A P/E (TTM) of 53.9 and EV/EBITDA of 37.7 sit against an FCF yield of only 2.81%, and debt climbed to $726.2M in FY 2025 from $103.9M i

Here is the bear case nobody on the bull side wants to address on HIMS: A P/E (TTM) of 53.9 and EV/EBITDA of 37.7 sit against an FCF yield of only 2.81%, and debt climbed to $726.2M in FY 2025 from $103.9M in FY 2024.. At 53.9x trailing P/E, even a small guidance miss in Medical/Nursing Services triggers a 12-15% air pocket.